scholarly journals Stratification of papillary thyroid cancer relapse risk based on the results of molecular genetic studies

2020 ◽  
Vol 10 (1) ◽  
pp. 93-100 ◽  
Author(s):  
S. A. Lukyanov ◽  
S. V. Sergiyko ◽  
S. E. Titov ◽  
I. V. Reshetov ◽  
Yu. A. Veryaskina ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Braf Mutation ◽  
Clinical Manifestations ◽  
Microrna Expression ◽  
Preoperative Treatment ◽  
American Thyroid Association ◽  
Papillary Thyroid ◽  
Study Objective ◽  
Risk Of Relapse

Introduction. Post-transcriptional mechanisms play a crucial role in the biological course and clinical manifestations of papillary thyroid cancer (PTC). Recent studies show that an increased content of oncogenic or reduced content of oncosuppressive microRNAs increases the aggressiveness of the tumor and correlates with an unfavorable prognosis of treatment, which allows them to be used in personalizing the treatment tactics of patients with PTC. The study objective is to compare the level of expression of 12 PTC-specific microRNAs and the frequency of V600E mutation of the BRAF gene in patients with different risk of relapse. Materials and methods. The study included 175 patients with PTC. For quantitative analysis of microRNA expression, a reverse transcription reaction followed by a real-time polymerase chain reaction in formalin-fixed paraffin blocks was used. Correlations between 12 microRNA expression and BRAF mutation with different clinical and anatomical features of PTC the risk of relapse according to the American Thyroid Association Risk Stratification System (2009) were analyzed. Results. We demonstrated that miR-146b, miR-221, miR-144, miR-451a, and miR-7 expression correlated with features such as extrathyroid tumor growth, larger size, multifocus, lymph node metastasis, and the presence of distant metastases of the PTC. Most importantly, miR-221, miR-144, miR-451a, and miR-7 expression correlated with risk levels, suggesting their potential significance in stratifying the risk of relapsing PTC. The dependence of the clinical behavior of PTC on the BRAF mutation has not been established.Conclusion. The result of the study will contribute to the individual choice of preoperative treatment tactics for patients with PTC. 

scholarly journals INFLUENCE OF BRAF MUTATION ON CLINICAL AND PATHOLOGICAL MANIFESTATIONS OF PAPILLARY THYROID CANCER

2020 ◽  
Vol 23 (2) ◽  
pp. 92-99
Author(s):  
S. A. Lukyanov ◽  
S. V. Sergiyko ◽  
S. E. Titov ◽  
G. O. Shcherbakov
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Braf Mutation ◽  
Clinical Stage ◽  
Molecular Genetic ◽  
Papillary Thyroid ◽  
Regional Lymph Nodes ◽  
Clinical Criteria ◽  
Increased Risk ◽  
Risk Of Relapse

Stratifications of the risk of recurrence and mortality in papillary thyroid cancer (PTC) are currently based on clinical criteria. In order to provide a more accurate assessment of the risk of relapse, new criteria, such as molecular genetic markers, are constantly being sought. The most studied of these markers is the BRAF mutation. The aim of the work was to study the dependence of clinical and pathological manifestations of papillary thyroid cancer on the presence of a BRAF mutation. The retrospective study included 212 patients with PTC. The dependence of the BRAF mutation on the patient’s gender, age, multifocality, presence of regional and remote metastases, extrathyroid invasion, clinical stage, and risk of relapse was studied. A single tumor was found in 196 (92.4%) cases, and a multifocal one in 16 (7.6%). Macroscopic extrathyroid invasion was observed in 80 (37.7%) patients. Metastases in regional lymph nodes were found in 83 (39.2%) patients, in 12 (5.7%) cases, the presence of distant metastases was detected. It was found that the BRAF mutation was present in 128 (60.4%) patients. There was no statistically significant association between the presence of the mutation and clinical and pathological manifestations of PTC, except for age. The incidence of the BRAF mutation in patients with PTC in young, middle, elderly and senile age was 3.8-35 times higher than in children and young men. It was found that the frequency of detection of the BRAF mutation increases with the age of the patient and has a linear relationship. It was concluded that the BRAF mutation can’t be used as an isolated marker of aggressive flow and a criterion indicating an increased risk of relapse of PTC.

scholarly journals The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAFV600E Mutation Status and Other Prognostic Factors

PLoS ONE ◽  
2015 ◽  
Vol 10 (7) ◽  
pp. e0132821 ◽  
Author(s):  
Agnieszka Czarniecka ◽  
Monika Kowal ◽  
Dagmara Rusinek ◽  
Jolanta Krajewska ◽  
Michal Jarzab ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Prognostic Factors ◽  
Papillary Thyroid Cancer ◽  
Papillary Thyroid ◽  
Brafv600e Mutation ◽  
Mutation Status ◽  
Risk Of Relapse

scholarly journals BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer

2005 ◽  
Vol 90 (12) ◽  
pp. 6373-6379 ◽  
Author(s):  
Mingzhao Xing ◽  
William H. Westra ◽  
Ralph P. Tufano ◽  
Yoram Cohen ◽  
Eli Rosenbaum ◽  
...  
Keyword(s):  
Multivariate Analysis ◽  
Thyroid Cancer ◽  
Risk Stratification ◽  
Papillary Thyroid Cancer ◽  
Braf Mutation ◽  
Advanced Tumor Stage ◽  
Papillary Thyroid ◽  
Clinical Prognosis ◽  
Mutation Status ◽  
Predictors Of Recurrence

Context: Use of BRAF mutation in papillary thyroid cancer (PTC) has the potential to improve risk stratification of this cancer. Objective: The objective of the study was to investigate the prognostic value of BRAF mutation in patients with PTC. Design, Setting, and Subjects: In a multicenter study of 219 PTC patients, data on their clinicopathological characteristics and clinical courses between 1990 and 2004 were retrospectively collected, and their tumor BRAF mutation status was determined. Associations of BRAF mutation with initial tumor characteristics and subsequent recurrence were analyzed. Main Outcome Measure: Relationships between the BRAF mutation status and clinicopathological outcomes, including recurrence, were measured. Results: We found a significant association between BRAF mutation and extrathyroidal invasion (P < 0.001), lymph node metastasis (P < 0.001), and advanced tumor stage III/IV (P = 0.007) at initial surgery. This association remained significant on multivariate analysis, adjusting for conventional clinicopathological predictors of recurrence excluding the histological PTC subtype, but was lost when the tumor subtype was included in the model. BRAF mutation was also significantly associated with tumor recurrence, 25 vs. 9% with and without mutation, respectively (P = 0.004), during a median of 15 (interquartile range, 3–29) months of follow-up. This association remained significant on multivariate analysis adjusting for conventional clinicopathological predictors of recurrence, even including the PTC subtype (odds ratio, 4.0; 95% confidence interval, 1.1–14.1; P = 0.03). BRAF mutation was even an independent predictor of recurrence in patients with stage I/II disease, 22 vs. 5% with and without BRAF mutation, respectively (P = 0.002). BRAF mutation was also more frequently associated with absence of tumor I-131 avidity and treatment failure of recurrent disease. Conclusions: In patients with PTC, BRAF mutation is associated with poorer clinicopathological outcomes and independently predicts recurrence. Therefore, BRAF mutation may be a useful molecular marker to assist in risk stratification for patients with PTC.

scholarly journals Blood prognostic predictors of treatment response for patients with papillary thyroid cancer

2020 ◽  
Vol 40 (10) ◽  
Author(s):  
Xiangxiang Liu ◽  
Zhongke Huang ◽  
Xianghui He ◽  
Xiangqian Zheng ◽  
Qiang Jia ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Poor Prognosis ◽  
Response To Therapy ◽  
Prognostic Indicators ◽  
High Morbidity ◽  
American Thyroid Association ◽  
Papillary Thyroid ◽  
Distribution Width ◽  
Prognosis Group

Abstract Background: Papillary thyroid cancer (PTC) is a very common malignant disease with high morbidity. We needed some pretreatment indicators to help us predict prognosis and guide treatment. We conducted a study about some pretreatment prognostic indicators. Methods: This clinical study recruited 705 postoperative PTC patients (211 males, 494 females). Clinical data before radioactive iodine (RAI) treatment were collected. Patients’ response to therapy were classified into two categories: ‘Good Prognosis Group’ (GPG) and ‘Poor Prognosis Group’ (PPG), according to ‘2015 American Thyroid Association Guidelines’. Differences of indicators between different prognosis groups were compared. Odds ratios (ORs) were calculated by univariate/multiple binary logistic regression models. Difference of body mass index (BMI) changes before and after RAI treatment between different prognosis groups was also compared. Results: A total of 546 (77.45%) belonged to GPG, and 159 (22.55%) belonged to PPG. Platelet (PLT), neutrophil (NEUT), PLT subgroups, and combination of red blood cell distribution width (RDW) and BMI (COR-BMI) were different between two prognosis groups. The significance of the difference between the two groups of BMI disappeared after the Bonferroni correction. PLT and PLT subgroups had detrimental effects on the risk of PPG; T stage had a positive effect on the risk of PPG. PLT subgroup showed a detrimental effect on the risk of PPG when we included additional covariates. Conclusions: We found that lower pretreatment PLT levels may indicate a poor prognosis for PTC. The relationship between platelet-derived growth factor (PDGF) and radiation sensitivity may be the key to this association.

Differential miRNAs expression in papillary thyroid cancer is associated with clinico-pathological features and BRAF mutation

2014 ◽  
Author(s):  
Esmeralda Castelblanco ◽  
Veronica Rosado ◽  
Montserrat Martinez ◽  
Maria Dolores Santos ◽  
Veronica Mancikova ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Braf Mutation ◽  
Pathological Features ◽  
Papillary Thyroid ◽  
Mirnas Expression
Sign in / Sign up

Export Citation Format

Share Document